StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

Investment analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

NASDAQ EVOK opened at $3.78 on Wednesday. The company’s fifty day moving average is $4.58 and its two-hundred day moving average is $4.73. The firm has a market capitalization of $5.62 million, a price-to-earnings ratio of -0.34 and a beta of 0.12. Evoke Pharma has a 52-week low of $3.44 and a 52-week high of $12.32.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent reporting period.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.